Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp383 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Detection of autoantibodies to osteoprotegerin in patients with rheumatoid arthritis and their association with disease activity

Hauser Barbara , Riches Philip , Gilchrist Tamara , Wilson Jim F , Fraser William D , Ralston Stuart H

Introduction: Osteoporosis and fragility fractures are recognized complications of rheumatoid arthritis (RA). Previously Riches et al. described a patient with celiac disease and severe osteoporosis in whom neutralizing antibodies to osteoprotegerin (OPG) were present. The aim of this study was to determine if OPG autoantibodies were present in patients with RA and other rheumatic diseases and to relate these to clinical features.Methods: We dev...

ba0002p80 | (1) | ICCBH2013

Osteogenesis imperfecta and short stature: effect of sclerostin antibody treatment in oim/oim mice

Cardinal Mickael , Nyssen-Behets Catherine , Ominsky Mike , Devogelaer Jean-Pierre , Manicourt Daniel H

Introduction: Osteogenesis imperfecta (OI) is characterized by low bone mass, skeletal fragility and, frequently, short stature. We previously showed in oim/oim mice that sclerostin inhibition increased bone mass, mineral content and strength. Here, we compared the body length and the sizes of long bones, head and vertebrae between oim/oim and wildtype mice and analyzed the effect of sclerostin antibody (Scl-Ab) on these parameters.Materials and methods:...

ba0003oc1.1 | Phosphate metabolism, fracture repair and osteoarthritis | ECTS2014

Type 2 cannabinoid receptor protects against osteoarthritis in mice

Sophocleous Antonia , Borjesson Anna E , Salter Donald M , Ralston Stuart H

Background: Cannabinoid receptors are expressed in synovial joints but their role in joint disease is unknown. Here we examined the role of the type 2 cannabinoid receptor (CB2) in the pathogenesis of age-related osteoarthritis and osteoarthritis caused by destabilisation of the medial meniscus (DMM) in WT and CB2-deficient mice (Cnr2−/− mice).Methods: The severity of arthritis was graded histologically according to standard techni...

ba0003oc2.1 | Osteoporosis epidemiology | ECTS2014

Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures – the openthyro register cohort

Abrahamsen Bo , Jorgensen Henrik L , Laulund Anne S , Nybo Mads , Brix Thomas H , Hegedus Laszlo

Objective: To assess the relationship between thyrotoxicosis and osteoporotic fractures in men and women.Design: Register-based cohort study in patients with a TSH measurement in the region of Funen 1996–2010. All determinations were done in the same lab serving all hospitals and GP practices. Persons with raised TSH or a history of thyroid/pituitary disease were not included.Results: The study population consisted of 222 138 ...

ba0003cc4 | (1) | ECTS2014

Two novel compound heterozygous mutations in LRP5 cause osteoporosis pseudoglioma syndrome

Alonso N , Soares D C , Kabir D , Summers G D , Ralston S H , Gregson C L

Osteoporosis pseudoglioma syndrome (OPPGS) is a rare autosomal recessive disorder characterised by congenital or juvenile-onset blindness, severe juvenile-onset osteoporosis, and skeletal fragility. OPPGS is caused by loss-of-function mutations in the LRP5 gene, a member of the LDL receptor family. It activates the canonical Wnt/β-catenin pathway, regulating osteoblastic bone formation. We investigated a 40-year-old Caucasian male presenting with congenital blind...

ba0005oc5.3 | Risk factors for fracture, Pagets disease of bone and musle and bone | ECTS2016

Osteoprotegerin autoantibodies are independently associated with low hip bone mineral density and increased fracture risk in patients with ankylosing spondylitis

Hauser Barbara , Zhao Sizheng , Visconti Micaela R , Riches Philip L , Goodson Nicola J , Ralston Stuart H

Osteoporosis and vertebral fractures are recognised complications of ankylosing spondylitis (AS) but the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a decoy receptor for RANK-L and inhibits osteoclastogenesis. We have previously demonstrated that antibodies to OPG (OPG-Ab) are associated with osteoporosis and increased bone turnover in patients with autoimmune diseases. The aim of this study was to determine whether OPG-Abs were detectable in AS pat...

ba0005p241 | Genetics and Epigenetics | ECTS2016

Identification of a novel locus on 2q13 of large effect size which predisposes to clinical vertebral fractures independently of BMD: the GEFOS consortium

Alonso Nerea , The Clinical Vertebral Fracture Consortium Nerea , Uitterlinden Andre , Rivadeneira Fernando , Ralston Stuart H

Vertebral fractures are the most common complication of osteoporosis, but little is known about the genetic determinants of susceptibility. Here we present the results of a genome wide association study in 1553 postmenopausal women with clinical vertebral fractures and 4340 controls, with replication in 667 cases and 2105 controls. A locus tagged by a less frequent variant (rs10190845, A-allele MAF=0.05) was identified on chromosome 2q13 as a strong predictor of clinical verte...

ba0006oc23 | (1) | ICCBH2017

Sustained radiographic and functional improvements with asfotase alfa treatment from up to 7 years in children with hypophosphatasia

Whyte Michael P. , Rockman-Greenberg Cheryl , Moseley Scott , Denker Andrew E. , McAlister William H.

Objective: Children with hypophosphatasia (HPP) treated with asfotase alfa in a Phase 2 study (NCT00952484) and its open-label extension (NCT01203826) experienced significant improvements in skeletal mineralization and physical function that were sustained through 5 years of treatment (1). Herein, we report data from these studies with a maximum of 7 years of treatment.Methods: Children with HPP aged 6–12 years at baseline received asfotase alfa (3 ...

ba0006p107 | (1) | ICCBH2017

A case of a novel de novo PLS3 deletion, presenting with vertebral fractures and mild dysmorphism

Doulgeraki A. , Costantini A. , Kampe A. , Karavitakis E. , Jantti N. , Krallis P. , Athanasopoulou H. , Xaidara A. , Makitie O.

Background: Mutations in the PLS3 gene, encoding plastin 3, cause X-linked osteoporosis. Osteoporosis is characterized by low bone mineral density (BMD) and increased susceptibility to fractures. Here we describe a 7-year-old boy with osteoporosis due to a novel PLS3 deletion.Presenting problem: The patient, born to non-consanguineous parents, had a history of one low-energy long-bone fracture, three vertebral fractures (T5, T6 T8) and kyphosis. DXA scan...